The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …

Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first
utilized in cancer management using radiopharmaceuticals to both image and selectively …

Targeted alpha particle therapy (TAT) has emerged as a promising strategy for the treatment
of prostate cancer (PCa). Actinium-225 (225Ac), a potent alpha-emitting radionuclide, may …

Following on from the 2015 Lancet Oncology Commission on expanding global access to
radiotherapy, Radiotherapy and theranostics: a Lancet Oncology Commission was created …

This paper is the first of a Series on theranostics that summarises the current landscape of
the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we …

Theranostics integrate molecular imaging and targeted radionuclide therapy for
personalised cancer therapy. Theranostic treatments have shown meaningful efficacy in …

Clinical trials of prostate-specific membrane antigen (PSMA) targeted radiopharmaceuticals
have shown encouraging results. Some agents, like lutetium-177 [177Lu] Lu-PSMA-617 …

Alpha theranostics offer an attractive alternative form of therapy, which has best been
investigated and documented with 225 Ac-PSMA in patients with prostate cancer …

Prostate cancer (PCa), a leading global health concern, profoundly impacts millions of men
worldwide. Progressing through two stages, it initially develops within the prostate and …

Molecular imaging of cancer is a collaborative endeavor, uniting scientists and physicians
from diverse fields. Such collaboration is actively develo** and translating cutting-edge …